Bispecific antibody
This page covers all Bispecific antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells, BCMA (B-cell maturation antigen), CD47 and CD40.
Targets
BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells · BCMA (B-cell maturation antigen) · CD47 and CD40 · PD-1 and LAG-3 · VEGF and ANG-2 · T-cell engager (exact targets not fully characterized in public literature) · Siglec-8 · CD16A and CD19 · PD-1 and CTLA-4 · CD30, CD16A
Marketed (3)
- Elrexfio · Pfizer · Oncology · 304
Bispecific antibody binding BCMA on myeloma cells and CD3 on T-cells, causing cytolysis. - Elrexfio · Pfizer · Oncology · 304
Bispecific antibody binding BCMA on myeloma cells and CD3 on T-cells, causing cytolysis. - Elrantamab · Pfizer · Oncology
Phase 3 pipeline (18)
- MRG004A plus best supportive care · Shanghai Miracogen Inc. · Oncology
MRG004A is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses. - BEP(500) · Institute of Cancer Research, United Kingdom · Oncology
BEP(500) is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance anti-tumor immune responses. - CHS-1420 · Coherus Oncology, Inc. · Oncology
CHS-1420 is a bispecific antibody that simultaneously engages CD47 on tumor cells and CD40 on antigen-presenting cells to enhance anti-tumor immunity. - GR1803 · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Oncology
GR1803 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses. - ABT-143 · AstraZeneca · Oncology
ABT-143 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses. - DB-1303/BNT323 · DualityBio Inc. · Oncology
DB-1303/BNT323 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses. - TAR-210 · Janssen Research & Development, LLC · Oncology
TAR-210 is a bispecific antibody targeting the PD-1 and LAG-3 immune checkpoint proteins. - HZT-501 · Amgen · Oncology
HZT-501 is a bispecific antibody that simultaneously engages two distinct immune pathways to enhance anti-tumor T-cell responses. - M701 · Wuhan YZY Biopharma Co., Ltd. · Oncology
M701 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses. - RO0503821 (1x/2 Weeks) · Hoffmann-La Roche · Oncology
RO0503821 is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance immune activation and tumor cell killing. - BNT323/DB-1303 · BioNTech SE · Oncology
BNT323/DB-1303 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to redirect immune responses against cancer cells. - MRG003 · Shanghai Miracogen Inc. · Oncology
MRG003 is a bispecific antibody that simultaneously engages tumor cells and immune cells to enhance anti-tumor immunity. - Rina-S · Genmab · Oncology
Rina-S is a bispecific antibody that simultaneously engages two immune checkpoints to enhance T-cell activation and anti-tumor immunity. - MAP0004 · Allergan · Oncology
MAP0004 is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance immune activation against cancer cells. - KSI-101 · Kodiak Sciences Inc · Ophthalmology
KSI-101 is a bispecific antibody that simultaneously targets VEGF and ANG-2 to reduce retinal inflammation and vascular leakage in retinal diseases. - HB1801 · Shanghai JMT-Bio Inc. · Oncology
HB1801 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses. - MRG002 · Shanghai Miracogen Inc. · Oncology
MRG002 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to enhance anti-tumor immunity. - Supportive care+Tacrolimus+Ripertamab · Air Force Military Medical University, China · Oncology
Ripertamab is a bispecific antibody that engages immune cells to target and eliminate cancer cells, combined with supportive care and tacrolimus immunosuppression.
Phase 2 pipeline (7)
- ABP-745 Dose C · Atom Therapeutics Co., Ltd
ABP-745 is a bispecific antibody that simultaneously engages two distinct molecular targets to modulate immune or disease-related pathways. - AK001 high dose · Allakos Inc. · Immunology
AK001 is a bispecific antibody that simultaneously engages Siglec-8 on eosinophils and mast cells while cross-linking them to trigger cell death and reduce type 2 inflammation. - AVE2635A · Sanofi · Oncology
AVE2635A is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses. - HM15211 · Hanmi Pharmaceutical Company Limited · Oncology
HM15211 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses. - Cell therapy with bispecific antibodies · Hadassah Medical Organization · Oncology
Bispecific antibodies redirect immune cells to recognize and eliminate cancer cells by simultaneously binding to tumor-associated antigens and immune cell receptors. - Bispecific antibody · Sung-Soo Park · Oncology
Binds to CD16A and CD19 to activate antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis - ABP-745 Dose A · Atom Therapeutics Co., Ltd · Oncology
ABP-745 is a bispecific antibody that targets and blocks PD-1 and CTLA-4 receptors.
Phase 1 pipeline (1)
- AFM 13 · Affimed GmbH · Oncology
AFM 13 is a tetravalent bispecific antibody construct that targets CD30 on tumor cells and CD16A on natural killer (NK) cells, enhancing NK cell-mediated cytotoxicity against CD30-positive tumors.